Flu Nasal Spray: Not About Pain, It's Science!

In the UK, children receive a flu vaccine as a nasal spray, a method chosen for its scientific advantages rather than to circumvent pain or anxiety. This approach stimulates local immunity directly within the nasal passages, the initial entry point for the influenza virus, while also generating systemic immune responses. This contrasts with injected flu vaccines, which primarily build antibodies circulating in the bloodstream.

While the nasal spray is generally suitable, specific circumstances dictate vaccine type. Clinical trials indicated an increased risk of wheezing and hospitalization in infants aged six to 23 months, leading to injections being administered to this age group. The live virus in the nasal spray is weakened and designed to function in the cooler nasal environment, a deliberate design distinct from contracting the actual flu.

Certain underlying health conditions can affect eligibility for the nasal spray. Although asthma does not automatically disqualify a child, active wheezing or recent increased use of reliever inhalers may necessitate an alternative vaccine. Importantly, egg allergies are no longer a contraindication for the nasal spray, though vaccination teams should be informed of any allergies. Side effects are typically mild, including runny nose or tiredness, and the risk of transmitting the weakened virus to others is very low.